摘要
目的：探讨重组人脑钠肽对老年慢性心力衰竭（CHF）患者血浆N-末端脑钠肽前体、尾加压素Ⅱ水平的影响，观察其临床效果。方法选取2011年11月-2012年11月在内蒙古医科大学附属医院老年病房住院的老年CHF患者60例，将其随机分为两组，每组各30例。治疗组给予重组人脑钠肽治疗，对照组给予硝酸甘油治疗。治疗前及治疗后1周观察两组用药前后呼吸困难程度、射血分数、血浆N-末端脑钠肽前体、尾加压素Ⅱ水平等生化指标的变化。结果用药前两组基本资料比较，差异无统计学意义（P〉0.05）。治疗后，治疗组射血分数[（37.1±4.6）%]、血浆N-末端脑钠肽前体[（3809±258）ng/L]、尾加压素Ⅱ水平[（10.3±3.4）ng/L]均优于对照组[（35.6±5.3）%、（4023±278）ng/L、（11.3±3.6）ng/L]，差异均有统计学意义（P〈0.05）。两组均未发生严重不良事件。结论重组人脑钠肽可使老年CHF患者呼吸困难减轻、全身状况改善、射血分数提高、血浆N-末端脑钠肽前体及尾加压素Ⅱ水平降低。
Objective To study the influence of recombinant human brain sodium peptide on the levels of plasma NT-pro BNP and urotensinII of patients with elderly chronic heart failure （CHF）, observe its clinical effect. Methods 60 patients with CHF form November 2011 to November 2012 in Geriatric Ward of the Affiliated Hospital of Inner Mon-golia Medical College were selected, and they were divide into two groups, with 30 cases in each group. The treatment group were given the treatment of natriuretic peptide, the control group were given the treatment of nitroglycerin. The degree of breathing difficulty, the change of biochemical index, such as ejection fraction, plasma NT-pro BNP and urotensin II of two groups before and 1 week after treatment were observed. Results The basic data of two groups be-fore treatment had no statistical difference （P 〈 0.05）. After treatment, the ejection fraction, plasma NT-pro BNP, urotensinII in the treatment group [（37.1±4.6）%, （3809±258） ng/L, （10.3±3.4） ng/L] were better than those of the con-trol group [（35.6±5.3）%, （4023±278） ng/L, （11.3±3.6） ng/L], the differences were statistically significant （P〈0.05）. There were no serious adverse events in two groups. Conclusion Natriuretic peptide can relieve dyspnea, improve the whole body condition, increase ejection fraction, drop the levels of plasma NT-pro BNP and urotensin II in elderly patients with CHF.
出处
《中国医药导报》
CAS
2014年第24期77-80,共4页
China Medical Herald
